2001
DOI: 10.1016/s0304-4017(01)00389-2
|View full text |Cite
|
Sign up to set email alerts
|

Long term improvement in the treatment of canine leishmaniosis using an antimony liposomal formulation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
30
0

Year Published

2002
2002
2024
2024

Publication Types

Select...
7
1
1

Relationship

1
8

Authors

Journals

citations
Cited by 39 publications
(34 citation statements)
references
References 11 publications
3
30
0
Order By: Relevance
“…Although the activation of complement appears to be an intrinsic property of lipid bilayers formed by cholesterol and electrically charged phospholipids (Devine et al 1994), laboratory changes associated of systems carriers of drugs can be observed in the absence of clinical effects (Valladares et al 2001).…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Although the activation of complement appears to be an intrinsic property of lipid bilayers formed by cholesterol and electrically charged phospholipids (Devine et al 1994), laboratory changes associated of systems carriers of drugs can be observed in the absence of clinical effects (Valladares et al 2001).…”
Section: Discussionmentioning
confidence: 99%
“…In that sense, the use of drug delivers, e.g. liposomes, provides satisfactory therapeutic responses in canine visceral leishmaniasis (CVL) (Valladares et al 2001, Frézard & Demicheli 2010. The properties of drug sustained release and targeting promote high concentrations of the encapsulated drug in the major sites of parasite infection, improving the drug effectiveness.…”
Section: Introductionmentioning
confidence: 99%
“…Once infection was confirmed and serologic results were positive, dogs were treated when protein and gamma globulin concentrations reached abnormally high values (Ͼ7 g/dl). All dogs were subjected to treatment with meglumine antimoniate (20 mg of Sb 5ϩ /kg of body weight every 12 h for 20 days) (38,50) and to a second treatment with liposome-encapsulated meglumine antimoniate (9.8 mg of Sb 5ϩ /kg every 24 h for 20 days) (51). One dog was treated again with liposome-encapsulated meglumine antimoniate and allopurinol (10 mg every 12 h for 8 months).…”
Section: Methodsmentioning
confidence: 99%
“…The present therapeutic protocol can be compared to that used by Valladares et al (11). In the latter work, dogs with VL were treated daily for 10 days with a liposome formulation of meglumine antimoniate at 9.8 mg Sb kg -1 day -1 (the first 2 doses admin- istered iv and the subsequent 8 doses administered subcutaneously).…”
Section: Da Schettini Et Almentioning
confidence: 99%